



Disparities between malaria infection and treatment rates: Evidence from a cross-sectional analysis of households in Uganda

Citation

Saran, Indrani, and Jessica Cohen. 2017. "Disparities Between Malaria Infection and Treatment Rates: Evidence from a Cross-Sectional Analysis of Households in Uganda." Edited by Luzia Helena Carvalho. PLOS ONE 12 (2) (February 27): e0171835. doi:10.1371/journal.pone.0171835

Published version

<https://doi.org/10.1371/journal.pone.0171835>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:36874129>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles (OAP), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#)

Title: Disparities between Malaria Infection and Treatment Rates: Evidence from a Cross-sectional Analysis of Households in Uganda

Indrani Saran^{1*}, Jessica Cohen²

¹Duke Global Health Institute, Duke University, Durham, NC, USA

²Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*Corresponding author

Email: ins289@mail.harvard.edu (IS)

1 **Abstract**

2 **Background**

3 In Sub-Saharan Africa, both under-treatment and over-treatment of malaria are common since
4 illnesses are often diagnosed and treated on the basis of symptoms. We investigate whether
5 malaria treatment rates among febrile individuals correspond to observed patterns of malaria
6 infection by age and by local prevalence.

7 **Methods and Findings**

8 We use data on treatment of febrile illnesses from a household survey that was conducted
9 between March and May 2012 in 92 villages in six districts in Eastern Uganda. All household
10 members were also tested for malaria using a rapid diagnostic test. We show that both the age of
11 the febrile individual and the village prevalence rate are strongly associated with the odds that a
12 febrile patient was infected with malaria, but not with the odds of ACT treatment. Compared to
13 individuals who were aged 15 or above, febrile individuals aged 5-14 had 3.21 times the odds of
14 testing positive for malaria 95% CI: [2.36 4.37], $P < 0.001$), and febrile individuals who were
15 under age 5 had 2.66 times the odds of testing positive for malaria (95% CI: [1.99 3.56],
16 $P < 0.001$). However, ACT treatment rates for febrile illnesses were not significantly higher for
17 either children ages 5-14 (Unadjusted OR: 1.19, 95% CI: [0.88 1.62], $P = 0.255$) or children under
18 the age of 5 (Unadjusted OR: 1.24, 95% CI: [0.92 1.68], $P = 0.154$). A one standard deviation
19 increase in the village malaria prevalence rate was associated with a 2.03 times higher odds that
20 a febrile individual under the age of five tested positive for malaria (95% CI: [1.63 2.54],
21 $p < 0.001$), but was not significantly associated with the odds of ACT treatment (Un-adjusted OR:

22 0.83, 95% CI: [0.66 1.05], P=0.113). We present some evidence that this discrepancy may be
23 because caregivers do not suspect a higher likelihood of malaria infection, conditional on fever,
24 in young children or in high-prevalence villages.

25 **Conclusion**

26 Our findings suggest that households have significant mis-perceptions about malaria likelihood
27 that may contribute to the under-treatment of malaria. Policies are needed to encourage
28 caregivers to seek immediate diagnostic testing and treatment for febrile illnesses, particularly
29 among young children.

30

31

32

33

34

35

36

37

38

39

40

41 **Introduction**

42 Malaria continues to pose a large morbidity and mortality burden with an estimated 214
43 million cases in 2015 and nearly 440,000 deaths [1]. A majority of these deaths occur in Sub-
44 Saharan Africa, primarily among young children, and could likely be avoided with prompt
45 treatment of the illness with artemisinin-based combination therapies (ACTs), the first-line
46 treatment for uncomplicated malaria [1,2].

47 In most countries, ACTs are freely available at public sector health facilities, and there
48 are efforts to make them available at subsidized prices in the private sector, where many people
49 first seek care for suspected malaria [3]. However, it is estimated that only 12-22% of malaria
50 cases in children under age five were treated with ACTs in 2014. This low level of coverage with
51 appropriate treatment is partly due to the fact that nearly 45% of children with fever (the primary
52 symptom of malaria) either did not get any care outside the home or sought care in the informal
53 private sector, where they are less likely to get ACTs than if they sought public sector treatment
54 [1]. Even when patients do use public health facilities, they do not always receive ACTs [1,4].

55 At the same time, many individuals who do *not* have malaria are treated with ACTs.
56 Malaria is often diagnosed and treated on the basis of symptoms such as fever, chills, headache,
57 fatigue, and nausea, which overlap with several other common bacterial and viral illnesses such
58 as pneumonia or the flu [5,6]. The World Health Organization (WHO) now recommends
59 universal diagnostic testing for malaria, and diagnostic confirmation of malaria cases in the
60 African public health sector has increased from 36% to over 60% between 2005 and 2014 [1].
61 However ACT treatment for non-malarial illnesses is still common, partly because many
62 individuals seek care in the private sector where diagnostic testing is very limited, but also

63 because health workers, caregivers and sick individuals often treat illnesses with ACTs even if
64 the individual tests negative for malaria [7–9].

65 Although it is difficult to identify malaria cases on the basis of symptoms alone, the age
66 of the individual and the local malaria prevalence are strong predictors of malaria infection status
67 [10,11]. For example, a review of studies across sub-Saharan Africa finds that the median
68 proportion of fevers attributable to malaria was 36% among children under five years and 26%
69 for those aged five and above[12]. Another study estimates that, across Africa, only 3.3% of
70 febrile children presenting at clinics in low malaria prevalence areas were infected with malaria,
71 but 59% of febrile children in high prevalence areas had malaria [13]. Models of malaria
72 transmission predict that, for children under the age of five, clinical incidence of malaria is
73 strongly increasing with prevalence [14,15]

74 In this study we investigate whether ACT treatment patterns for febrile illnesses
75 correspond to patterns of malaria infection by patient age and by local prevalence. We focus on
76 age and prevalence as these are two factors that have been shown to be strongly correlated with
77 the probability of malaria infection in febrile patients. We hypothesized that patterns of ACT
78 treatment are related to household beliefs about the likelihood of a febrile illness being malaria.
79 In order to test this, we also examine how malaria beliefs vary with the age of the febrile
80 individual and with local prevalence. In addition, we directly examine the association between
81 malaria beliefs and ACT treatment and compare this to the association between other household,
82 respondent, and febrile individual characteristics hypothesized to be important for ACT
83 treatment. We use data from a unique household survey in Eastern Uganda that asked about
84 household malaria treatment behavior and malaria beliefs, and also included a malaria rapid

85 diagnostic test of all household members. This study provides evidence on the extent to which
86 household beliefs about malaria may contribute to the under-treatment of malaria.

87

88 **Methods**

89 **Ethics Statement**

90 Ethical approval for this study was granted by the Harvard School of Public Health
91 Internal Review Board (Protocol# P19371-105) and the Uganda National Council for Science
92 and Technology (Protocol # HS805). Written consent was obtained from all interviewed
93 respondents.

94

95 **Study Context and Population**

96 This study used data from a household survey that was conducted over 9 weeks between
97 March and May 2012 in 92 villages in six districts in Eastern Uganda: Budaka, Bukedea,
98 Kibuku, Kumi, Ngora and Pallisa. Malaria is highly endemic in this region with over 100
99 infective bites per person per year and peaks in transmission during the rainy seasons which
100 occur in the months of March through May and September to December [16].

101 The household survey was conducted as part of a randomized controlled trial that tested
102 the feasibility and impact of introducing rapid diagnostic tests for malaria in private sector drug
103 shops, described in more detail in previously published work [9,17]. 2,285 households were
104 visited for a baseline survey in March and April 2011 and were visited again for monthly follow-
105 up surveys for nine months to ask about illnesses household members experienced in the month

106 prior to the survey. This analysis used only the last survey round, when all consenting adults and
107 all children whose parents or caregivers gave consent for them, were tested for malaria using a
108 rapid diagnostic test (RDT). The RDT used in this study was the CareStart Malaria HRP2 (Pf)
109 test (Access Bio, Somerset, USA). This test has a panel detection score of 98.7%, a false-
110 negative rate of < 1% and a total false-positive rate of 2.4% [18].

111

112 **Data**

113 The survey asked the female household head (i.e. the female primarily responsible for
114 household health decisions) to list illnesses that any member of the household had in the month
115 prior to the survey, including the start and end date. For children under the age of 18, in 75% of
116 cases the respondent was the mother of the patient and in 13% of cases she was the grandparent
117 (in the remaining cases, the respondent was another relative, like an aunt). The respondent was
118 questioned about the symptoms experienced, and was also specifically asked if the sick
119 individual had any of a number of symptoms including fever, chills, headache, joint pain, loss of
120 appetite, diarrhea, vomiting, stomach pains and runny nose/congestion. The respondent was then
121 asked about the sequence of treatments sought for the illness, what drugs were obtained, whether
122 the sick individual was tested for malaria, and the result of the test. Respondent perceptions of
123 the likelihood that the illness was malaria were elicited using a visual analog ladder scale.

124 We supplemented this data on illness treatment with household demographic information,
125 and with data from a census of all local public health facilities and licensed drug shops, also
126 conducted as part of the main study, which included the GPS co-ordinates of the facilities and
127 information about ACT stocks.

128 **Analytical Approach**

129 We investigated whether ACT treatment for febrile illnesses, and beliefs about whether a
130 febrile illness was malaria, corresponded to patterns of malaria infection (as measured by the
131 RDT) by the age of the febrile individual and by the village prevalence rate. We focused on
132 febrile illnesses, as fever is the symptom most strongly associated with malaria and is also used
133 as a WHO indicator of suspected malaria in malaria-endemic areas [1,2]. Since no formal
134 definition of fever was given to the respondent, our analysis relied on febrile illnesses as self-
135 reported by the respondent. Importantly, since the RDT was performed at the end of the survey,
136 respondents did not know the RDT result of household members when responding to questions
137 about ACT use and malaria likelihood.

138 The RDT identifies a malaria infection by detecting the presence of an antigen known as
139 histidine-rich protein 2 (HRP) which can persist several weeks after the malaria infection has
140 cleared [19]. Studies have found that 88-98% of individuals still have a positive RDT test result
141 14 days after beginning treatment [20–22]. The RDT, therefore, is not only a measure of a
142 current infection, but can also detect one that may have been treated and cured up to two weeks
143 before the test. Our sample, therefore, consisted of all febrile episodes that ended no more than
144 14 days prior to the date of the survey (which was also the date of the RDT). This methodology
145 for measuring malaria infection and treatment rates is also used by the World Health
146 Organization in the two most recent “World Malaria Reports” [1,23].

147 Our first outcome of interest was whether a febrile individual had clinical malaria. We
148 defined a febrile illness as malaria if it ended no more than two weeks before the survey and the
149 patient tested positive for malaria on the survey RDT.

150 Our second outcome of interest was whether the febrile individual was reported to have
151 been treated with an ACT at any time during the illness episode. For each illness, the respondent
152 was asked what drugs were used at home, and what drugs were given or purchased at a health
153 facility or drug shop. A drug was coded as an ACT either if the respondent said it was an ACT,
154 or gave the name or brand of a particular type of ACT (such as “Coartem” or “Lumartem”). We
155 excluded from the analysis the 7 individuals who reported previously testing negative for
156 malaria, but tested positive for malaria when we performed the RDT at the end of the survey.
157 These individuals may have become infected between the time they sought treatment for their
158 illness and the survey and their fever may have been due to another cause.

159 Our final outcome of interest was whether the respondent believed that the febrile
160 individual’s illness was malaria. One measure of the respondent’s beliefs about whether the
161 illness was malaria was if she mentioned “malaria” when asked what the febrile individual’s
162 health problem was. However, some respondents simply gave symptoms in response to this
163 question. For all febrile illnesses, respondents were also asked what they thought was the
164 likelihood that the illness was malaria on a visual analog ladder scale from 0 (no chance of
165 malaria) to 10 (definitely malaria). Therefore, we defined a respondent as believing an illness
166 was malaria if she either reported the health problem as “malaria”, or if she gave a rating
167 between 8 and 10 on the 0-10 scale. While the proportion of febrile illnesses perceived to be
168 malaria was sensitive to the way this variable is defined, the patterns of beliefs by age of the
169 individual, and by village prevalence, were generally similar regardless of how we defined a
170 respondent’s beliefs about whether a febrile illness was malaria (S1 Fig). In all analyses that
171 include respondents’ beliefs about whether the illness was malaria, we excluded the 165 febrile

172 individuals who had already received a malaria test, as the respondents' beliefs may have been
173 influenced by the test result.

174 Our two independent variables were the age of the febrile individual and the village
175 malaria prevalence rate. Prevalence was defined as the proportion of 2-10 year olds in the village
176 who tested positive for malaria on the RDT (regardless of whether they reported any symptoms).
177 We used the proportion of 2-10 year olds testing positive, instead of the proportion of all ages
178 testing positive, as this is considered a stable measure of local prevalence [24]. We excluded the
179 febrile individual's own RDT status when calculating the village prevalence rate for each
180 individual. Furthermore, when investigating the relationship between village prevalence and the
181 outcomes of interest, we limited the sample to children under the age of five. For older ages, the
182 relationship between malaria prevalence and clinical incidence is not straightforward because in
183 high-prevalence areas, adults are likely to have higher natural immunity to the disease resulting
184 from greater exposure to the parasite when young [15,25].

185 We provide graphical evidence to show how each of the outcomes vary with the age, and
186 with the village malaria prevalence rate, of individuals who had a fever in the two weeks prior to
187 the survey. We binned febrile individuals ages into 1-year age groups for individuals under the
188 age of 5, and 5-year age groups for individuals aged 5 and above. For village prevalence rates—
189 which ranged from 0.08 to 0.93— we divided them into 0.10 unit bins. The mean of the outcome
190 (malaria positivity rates, ACT treatment rates, malaria beliefs) was calculated within each bin
191 and plotted against febrile individual age and, separately, against village prevalence rates. On the
192 same graphs, we also included a local polynomial or local linear regression line, and 95%
193 confidence intervals, of the outcome on the independent variable of interest (for the regression
194 line we do not bin age/village prevalence).

195 We used logistic regressions to test whether the graphical relationships were statistically
196 significant and to control for other factors that might influence ACT use and also be associated
197 with our variables of interest. The control variables, which have been shown to either influence
198 treatment-seeking for febrile illnesses, or to be directly associated with the use of ACTs,
199 included the education level of the respondent, whether he/she could read a basic letter in
200 English, the wealth quintile of the household, the distance of the household to the closest health
201 center, hospital, clinic, and drug shop, and whether ACTs were available at the closest licensed
202 drug shop at the time of the survey [4,26–31]. We tested the equality of coefficients from
203 separate models with either malaria positivity as an outcome or ACT treatment as an outcome
204 using the “suest” command in STATA which estimates both models simultaneously.

205 In addition, we show both the bi-variate and multi-variate associations between ACT
206 treatment—for both febrile illnesses and RDT-positive febrile illnesses— and respondents’
207 beliefs about whether the illness was malaria, the age of febrile individual, village prevalence
208 and the control variables. For the multi-variate model, we also performed stepwise backward-
209 selection estimation of a logistic model (using the “stepwise” command in STATA). The
210 significance level for removal from the model was 0.2.

211 We defined a respondent as having some primary education if they completed part of, or
212 all of, primary school (but had no further education). A respondent was defined as having some
213 secondary education if they had any education beyond primary school. We assigned households
214 to wealth quintiles using a principal component analysis of housing characteristics and household
215 ownership of durable assets and farm animals [32]. Distance to the nearest health facility and
216 drug shop was based on the GPS co-ordinates of the households and the health facilities, and was
217 calculated using the length of the shortest curve between the two GPS co-ordinates along the

218 surface of a mathematical model of the earth. A drug shop was defined as stocking ACTs if the
219 drug shop attendant mentioned it as one of the five most frequently sold anti-malarial drugs. This
220 variable was missing for 156 people in the sample. For 93 of these people, the missing value was
221 imputed as the mean proportion of drug shops in the person's village that had ACTs available.
222 All regressions with ACT stocks also include an indicator variable to indicate which of these
223 observations had missing values that were imputed.

224 In all regressions, standard errors were adjusted for clustering at the village level (using
225 the STATA cluster command) as this was the level at which households were randomly sampled.
226 All analyses were conducted using Stata/SE version 11 (StataCorp, College Station, TX) [33].
227

228 **Results**

229 **Sample Characteristics and Malaria Positivity Rates**

230 The survey was conducted with respondents from 2,285 households and included 9,887
231 individuals as members of those households. Table 1 presents some summary statistics on the
232 1,342 individuals who had a fever in the two weeks prior to the survey and on the respondents
233 for these individuals. 20% of respondents had no education, while 62% had some primary
234 education. Only 31% could read a simple letter in English. Febrile individuals were from
235 households that were relatively poor: while 83% owned some land, only 5% had electricity, and
236 57% owned at least one mobile phone.

237

238

239
240

Table 1. Summary Statistics of Respondent, Household, and Febrile Individual Characteristics and Treatment-Seeking Behavior.

	% or Mean ±SD	Observations
<i>A. Characteristics of Respondent</i>		
Age	35.0 ± 12.4	1288
Female	96%	1338
No Education	20%	1334
Some Primary Education	62%	1334
Some Secondary Education	17%	1334
Can Read English	31%	1342
<i>B. Characteristics of Household</i>		
Has Electricity	5%	1340
Owns Mobile Phone	57%	1342
Owns Land	83%	1342
Number of Household Members	7.33 ± 3.40	1342
Village Malaria Prevalence Rate in 2-10 year olds	63%	1342
Village Malaria Prevalence Rate among all ages	48%	1342
<i>C. Household Distance to Health Facilities</i>		
Distance to closest Health Center (km)	2.01 ± 1.81	1341
Distance to closest Hospital (km)	10.2 ± 5.67	1341
Distance to closest private clinic (km)	3.50 ± 3.34	1341
Distance to closest drug shop (km)	0.79 ± 0.91	1341
Distance to closest licensed drug shop (km)	1.61 ± 1.70	1341
ACTs available at closest licensed drug shop	82%	1279
<i>D. Characteristics of Febrile Individual</i>		
Age	13.9 ± 18.0	1312
Under 5	44%	1342
Female	58%	1342
Tested Positive for Malaria	52%	1342
<i>E. Treatment-Seeking for Febrile Illness</i>		
Ever Sought Care	58%	1342
Sought Care in Public Sector	20%	1342
Sought Care at Private Clinic	7%	1342
Sought Care at Drug Shop	33%	1342
<i>F. Malaria Testing and Treatment</i>		
Ever Tested at Health Facility/Drug Shop	12%	1335
Tested Positive for Malaria (Among Those Tested)	76%	172
Took ACT anywhere	42%	1342
Took ACT if Treated at Home	36%	559
Took ACT if Treated Outside Home	46%	783

Took ACT if Tested Positive at Health Facility/Drug Shop	54%	131
Took Other Anti-Malarial Drug	21%	1342
Respondent Reported Illness Was Malaria	34%	1342

241 Sample is limited to individuals who had a fever in the two weeks prior to the survey.

242

243

244 The mean village malaria prevalence rate was 63% in children aged 2-10 years. The
 245 distance to the closest health center was, on average, 2 km, while the mean distance to the closest
 246 drug shop (either licensed or unlicensed) was less than half of that at 0.8km. 82% of households
 247 had ACTs available at their closest licensed drug shop which was, on average, 1.6km away.

248 584 of the 1,342 (44%) febrile episodes were among children under the age of five.

249 Among the 1,342 febrile episodes, 702 (52%) tested positive for malaria when they were tested
 250 at the end of the survey, and 343 children under the age of five (59%) tested positive for malaria
 251 at the end of the survey. 58% of febrile individuals received care from outside the home for their
 252 febrile illness, 33% went to a drug shop, while 20% were treated in the public sector.


253 Only 12% of febrile individuals had received a diagnostic test for malaria at either a
 254 health facility or drug shop. Of those tested, 76% reported a positive test, and 54% of those who
 255 said they tested positive reported taking an ACT. 36% of febrile individuals who did not seek
 256 care outside the home reported taking an ACT, while 46% of people who sought care outside the
 257 home said they took an ACT. Among all febrile individuals, 21% reported taking a non-ACT
 258 antimalarial. Respondents reported 34% of the febrile illnesses as malaria.

259 **Malaria Positivity and ACT use by Age of Febrile individual and by**

260 **Village Prevalence**

261 Fig 1 shows how malaria infection rates and ACT use varied with the age of febrile
262 individuals. The malaria positivity rate in febrile individuals declined substantially with age,
263 from 60% to 30% between the ages of 0-45 (Fig 1A). Compared to febrile individuals who were
264 aged 15 or above, febrile children aged 5-14 had 3.21 times the odds of testing positive for
265 malaria (95% CI: [2.36 4.37], $P < 0.001$), and febrile children who were under 5 had 2.66 times
266 the odds of testing positive for malaria (95% CI: [1.99 3.56], $P < 0.001$) with very similar effects
267 when adjusted for covariates (S1 Table). However, febrile children were not comparatively more
268 likely to be treated with an ACT than febrile individuals aged 15 or above (Fig 1B). Compared to
269 those aged 15 or above, the odds of being treated with an ACT were not significantly higher for
270 children under the age of 5 (Unadjusted OR: 1.24, 95% CI: [0.92 1.68], $P = 0.154$; Adjusted OR:
271 1.20, 95% CI [0.87 1.64], $P = 0.269$) or children ages 5-14 (Un-adjusted OR: 1.19, 95% CI: [0.88
272 1.62], $P = 0.255$, Adjusted OR: 1.29, 95% CI: [0.94 1.77], $P = 0.112$) (S1 Table).

Malaria Positivity and ACT use by Age Conditional on Fever



273


274 **Fig 1. Malaria Infection Rates and ACT Use by Age.** (A) The proportion of febrile individuals
 275 who tested positive for malaria on the RDT. (B) The proportion of febrile individuals who were
 276 treated with an ACT. Figure shows mean of the outcome within 1 year (for ages under 5) or 5-
 277 year (for ages 5 and above) age groups. A local polynomial regression line is also plotted and the
 278 grey shaded areas indicate 95% confidence intervals. Data is limited to individuals who had a
 279 fever in the two weeks prior to the survey. Ages above 60 are excluded because of small sample
 280 size.

281

282 Our sample consisted of febrile individuals living in villages with malaria prevalence
 283 rates in 2-10 year olds ranging from 8% to 93% (S2 Fig). The malaria positivity rate in febrile
 284 individuals under the age of five increased from 0% in the lowest prevalence villages to 84% in
 285 the highest prevalence villages (Fig 2). A one standard deviation increase in the village
 286 prevalence rate was associated with 2.03 times higher odds that a febrile child under the age of
 287 five tested positive for malaria (95% CI: [1.63 2.54], $p < 0.001$; Adjusted OR: 1.68, 95% CI: [1.31

288 2.16], $p < 0.001$) (S2 Table). However, the likelihood that a febrile child was treated with an
289 ACT does not increase with village prevalence (Fig 2). A one standard deviation increase in the
290 village prevalence rate was associated with lower odds that a febrile episode in a child under 5
291 was treated with an ACT (Unadjusted OR: 0.83, 95% CI: [0.66 1.05], $P = 0.113$; Adjusted OR:
292 0.75, 95% CI: [0.60 0.93], $P = 0.010$) (S2 Table).

Malaria Positivity and ACT use by Village Prevalence Rates Conditional on Fever



293

294 **Fig 2. Malaria Infection Rates and ACT Use by Village Prevalence.** (A) The proportion of
295 febrile individuals who tested positive for malaria on the RDT. (B) The proportion of febrile
296 individuals who were treated with an ACT. Figure shows mean of the outcome within 0.10 units
297 of village prevalence. A local linear regression line is also plotted and the grey shaded areas
298 indicate 95% confidence intervals. Data is limited to individuals who had a fever in the two
299 weeks prior to the survey and to individuals under the age of five.

300


301 The odds that a clinical malaria episode (a fever with a positive RDT) was treated with an
302 ACT was also not significantly associated with the age of the febrile individual age and was
303 lower with increasing village malaria prevalence rates (S3 Fig, S1 Table, S2 Table).

304

305 **Malaria Beliefs**

306 We now turn from treatment of febrile illnesses to beliefs about whether the illness was
307 malaria. Respondents reported 34% of febrile illnesses across all ages as malaria, with a slightly
308 higher percent among febrile individuals aged 20-30 (Fig 3). Compared with febrile individuals
309 ages 15 and above, respondents did not have higher odds of reporting that the illness was malaria
310 for children ages 5-14 (Unadjusted OR: 1.04, 95%CI:[0.71 1.53], P=0.829; Adjusted OR: 1.17,
311 95% CI:[0.80 1.70], P=0.421) or children under the age of 5 (Unadjusted OR: 0.94, 95% CI:
312 [0.72 1.24], P=0.677; Adjusted OR: 0.97, 95% CI:[0.71 1.33], P=0.863) (S3 Table). Similarly,
313 Fig 3 suggests that beliefs about whether a febrile illness in a child under 5 was malaria were not
314 associated with malaria prevalence. A one standard deviation increase in the village malaria
315 prevalence rate was associated with 0.87 times the odds that a respondent identified a febrile
316 illness in a child under 5 as malaria (95% CI: [0.70 1.08], P=0.213, Adjusted OR: 0.89, 95% CI:
317 [0.70 1.14], P=0.365) (S3 Table).

Malaria Beliefs by Age and Prevalence Conditional on Fever



318

319 **Fig 3. Malaria Beliefs by Age and Prevalence.** (A) The proportion of febrile illnesses reported
 320 as malaria by the age of the febrile individual. (B) The proportion of febrile illnesses reported as
 321 malaria by the village prevalence rate. Figure shows mean of the outcome within 1-year age
 322 groups (for children under 5) or 5-year age groups (for ages 5 and above) and 0.10 units of
 323 village prevalence. A local linear regression line is also plotted and the grey shaded areas
 324 indicate 95% confidence intervals. Sample is limited to individuals who had a fever in the two
 325 weeks prior to the survey and who were not previously tested for malaria. Ages above 60 are
 326 excluded because of small sample size. In Figure 3B, sample is limited to children under the age
 327 of 5.

328

329

330 **Factors Associated with ACT treatment for Febrile Illnesses**

331 Table 2 compares the magnitude of the bi-variate and multi-variate associations between
 332 respondent, febrile individual, and household characteristics and use of ACTs to treat a febrile
 333 illness (Columns 1 and 2) and ACT treatment of RDT-positive febrile episodes (Columns 3 and
 334 4). A febrile individual who was believed by the respondent to have malaria had 2.54 times the
 335 odds of being treated with an ACT (95% CI: [1.86 3.47], P<0.001, Adjusted OR: 2.43, 95% CI:
 336 [1.78 3.33], P<0.001), which suggests that people’s perceptions of whether an illness is malaria
 337 are important in influencing the probability that a febrile individual is treated with an ACT.
 338 Similarly, a clinical malaria episode (an individual who had a fever and tested positive for
 339 malaria on the survey RDT) had 2.73 times higher odds of being treated with an ACT if the
 340 respondent believed the illness was malaria (95% CI: [1.83 4.07], P<0.001, Adjusted OR: 2.68,
 341 95% CI: [1.79 4.01], P<0.001).

342

343 **Table 2: Factors Associated with ACT use for Febrile Episodes and Clinical Malaria**
 344 **Episodes**

	Febrile Episode Treated with ACT		RDT-Positive Febrile Episode Treated with ACT	
	OR	aOR	OR	aOR
Respondent Believed Illness Was Malaria	2.54** [1.86,3.47]	2.43** [1.78,3.33]	2.73** [1.83,4.07]	2.68** [1.79,4.01]
Individual is Aged 15 and above	Ref. Group	Ref. Group	Ref. Group	Ref. Group
Child Aged 5-14	1.24 [0.89,1.71]	1.32 [0.94,1.86]	1.23 [0.79,1.91]	1.49 [0.93,2.40]
Child Under Age 5	1.21 [0.87,1.68]	1.18 [0.84,1.64]	1.39 [0.88,2.19]	1.43 [0.91,2.26]
	0.87	0.85*	0.84	0.73*

Standardized Village Prevalence Rate	[0.72,1.06]	[0.73,0.99]	[0.62,1.14]	[0.55,0.97]
Respondent Has No Education	Ref. Group	Ref. Group	Ref. Group	Ref. Group
Respondent Has Some Primary Education	2.31** [1.51,3.55]	2.15** [1.38,3.36]	1.98* [1.15,3.41]	1.80* [1.06,3.07]
Respondent Has Some Secondary Education	3.02** [1.67,5.47]	1.92 [0.93,3.96]	2.12* [1.02,4.40]	1.44 [0.65,3.20]
Respondent Can Read English	1.64** [1.21,2.21]	1.18 [0.77,1.81]	1.37 [0.93,2.01]	1.29 [0.79,2.10]
Household In First Wealth Quintile (Poorest)	Ref. Group	Ref. Group	Ref. Group	Ref. Group
Household In Second Wealth Quintile	1.22 [0.79,1.88]	1.06 [0.67,1.65]	1.35 [0.79,2.31]	1.08 [0.64,1.85]
Household In Third Wealth Quintile	0.98 [0.66,1.48]	0.92 [0.61,1.38]	1.1 [0.69,1.75]	1.01 [0.62,1.65]
Household In Fourth Wealth Quintile	1.61 [0.95,2.71]	1.5 [0.90,2.51]	1.09 [0.55,2.14]	1.13 [0.60,2.11]
Household In Fifth Wealth Quintile (Richest)	1.84* [1.05,3.24]	1.33 [0.73,2.42]	1.26 [0.56,2.83]	0.79 [0.33,1.89]
Household distance to closest health center (km)	1 [0.90,1.12]	1.04 [0.96,1.12]	1 [0.87,1.15]	1.03 [0.93,1.15]
Household distance to closest hospital (km)	0.99 [0.96,1.01]	1 [0.98,1.02]	0.98 [0.94,1.02]	0.98 [0.95,1.01]
Household distance to closest clinic (km)	0.97 [0.92,1.02]	0.98 [0.93,1.03]	0.99 [0.92,1.06]	0.98 [0.92,1.04]
Household distance to closest drug shop(km)	1.16* [1.04,1.31]	1.16* [1.03,1.30]	1.25** [1.08,1.44]	1.23** [1.08,1.40]

ACTs available at closest licensed drug shop	1.36 [0.89,2.08]	1.47* [1.07,2.00]	1.56 [0.83,2.92]	1.76* [1.08,2.86]
Proportion Treated with an ACT	0.4	0.4	0.39	0.39
Number of Obs	1103	1103	597	597

345

346 Notes: Columns 1 and 2 show associations with the odds of ACT treatment for a febrile illness,
 347 while Columns 3 and 4 present associations with the odds of ACT treatment for an RDT-positive
 348 febrile illness. Columns 1 and 3 are bi-variate regressions and columns 2 and 4 are multi-variate
 349 regressions. Confidence intervals are in brackets and adjusted for clustering at the village level.
 350 *p<0.05, **p<0.01

351

352 In the multi-variate regression (Column 2), odds of ACT treatment for a febrile episode
 353 was higher if the respondent had some primary education (Adjusted OR:2.15, 95% CI: [1.38
 354 3.36], P=0.001), if ACTs were available at the closest drug shop (Adjusted OR:1.47, 95% CI:
 355 [1.07 2.00], P=0.016) and as distance to the closest drug shop increased (Adjusted OR:1.16, 95%
 356 CI: [1.03 1.30], P=0.012) with similar results for the odds of ACT treatment for RDT-positive
 357 febrile episodes (Column 4). In both the bi-variate and multi-variate regressions, age was not
 358 significantly associated with the odds of ACT treatment for both febrile episodes and clinical
 359 malaria episodes and in the multi-variate models, increasing village malaria prevalence was
 360 associated with statistically significant lower odds of ACT treatment. Results from using a
 361 stepwise approach to estimate the model are very similar (S4 Table).

362

363 **Discussion**

364 Nearly 80% of children with malaria worldwide do not receive ACTs [1]. Using a
 365 household survey from Uganda, and the WHO methodology for appropriate treatment of malaria,
 366 we found that, although the age of the febrile individual and the village prevalence rate were

367 strongly associated with malaria infection among febrile individuals, ACT treatment rates were
368 not correspondingly higher among young children or in high-prevalence villages. Moreover,
369 people's beliefs about whether a febrile illness was malaria did not vary with the age of the
370 febrile individual or with village prevalence, which suggests that household misperceptions
371 about malaria risk may play an important role in the under-treatment of malaria.

372 We show that respondents' beliefs about malaria are strongly associated with the odds
373 that a febrile individual was treated with an ACT, even when controlling for other factors that
374 might influence ACT treatment and be associated with beliefs about malaria likelihood. We also
375 find associations between ACT treatment and whether the respondent had a primary education,
376 whether ACTs were available at the closest drugs shop, and with distance to the closest drug
377 shop. These results are consistent with previous studies indicating the importance of education
378 and access to drugs in malaria treatment [26,31,34]. The positive association between distance to
379 a drug shop and ACT treatment is, however, unexpected. While we do not have any evidence on
380 why this is the case, one possible explanation is that households further from a drug shop may be
381 more likely to visit a health facility and, therefore, have a higher likelihood of receiving ACT
382 treatment.

383 It is possible that the inverse relationship we observe between the proportion of children
384 treated with an ACT and village prevalence results from variations in ACT coverage across
385 different villages. For example, villages with the highest ACT coverage rates could be expected
386 to have the lowest prevalence of malaria due to potential effects of ACT treatment on reducing
387 malaria transmission (particularly in low-transmission settings) [35–38]. However, we did not
388 find substantial variations across villages in the availability of ACTs at either public health
389 facilities or at licensed drug shops— in villages across all prevalence levels, more than 90% of

390 public health facilities had ACTs available at the time of the survey, while approximately 80% of
391 licensed drug shops had ACTs available (S4 Fig). This suggests that the patterns of ACT
392 treatment by village prevalence are not simply a result of variations in ACT access.

393 We also found that among those who received diagnostic testing for malaria, and tested
394 positive, only 54% of sick individuals took an ACT (a much higher proportion- 91% took any
395 type of anti-malarial drug). This indicates that additional efforts are needed to increase the
396 availability and affordability of ACTs. Our results on malaria beliefs also suggest, however, that
397 households may not seek malaria testing and treatment for fevers that they do not suspect to be
398 malaria. This underscores the urgency of public health messaging that emphasizes the
399 importance of all fevers being tested for malaria and receiving appropriate treatment for the
400 illness. Furthermore, the messaging could focus on the importance of febrile individuals getting
401 tested even when the caregiver believes the illness is unlikely to be malaria, because of the
402 difficulty of identifying the disease on the basis of symptoms alone. In order for this policy to be
403 successful, there will also need to be improved access to diagnostic testing, as well as
404 interventions to raise confidence in malaria diagnostic testing which has varied across different
405 contexts [7–9,39,40] .

406 It is particularly concerning that children are under-treated with ACTs. Not only are
407 children more likely than adults to have malaria, but the disease is more likely to develop into a
408 severe and life-threatening illness in children [41]. Several studies have found no differences in
409 treatment-seeking patterns, or in the probability of being treated with an ACT, by the age of the
410 sick individual [27,30,31,42]. Our results suggest that this may be related to caregivers' mis-
411 perceptions about the relative likelihood of malaria in febrile children compared to febrile adults.

412 This study has some limitations. First, people who have developed immunity to the
413 disease can harbor malaria parasites asymptotically [43] and may test positive on the RDT
414 even if their fever is caused by another illness. Since we do not have data on parasite densities or
415 co-infection, we cannot identify the proportion of fevers that are attributable to malaria using
416 logistic regression methods [44,45]. However, according to WHO guidelines, all individuals
417 with a fever who test positive for malaria should be treated with ACTs and therefore this is the
418 definition that we use to identify illnesses that should have received ACT treatment [2].
419 Furthermore, immunity to malaria disease generally develops with age, particularly in areas of
420 high malaria transmission [25,43]. When comparing across villages with different malaria
421 prevalences, we limit our analysis to children under the age of five for whom there is a consistent
422 relationship between increasing prevalence and higher incidence of clinical malaria episodes
423 [15].

424 Second, the malaria RDT we used in this study only detects infections caused by
425 *Plasmodium falciparum* and, therefore, we may have missed infections that were caused by non-
426 *falciparum* species [46]. However in Uganda, *P. falciparum* is responsible for between 90-97%
427 of malaria cases [47].

428 Third, we relied on respondents' self-reports of whether an individual had a fever in the
429 two weeks prior to the survey and of whether the individual took an ACT. This may be affected
430 by recall bias, social desirability bias and respondent knowledge of ACTs. By relying on
431 respondents' self-reports of whether the individual had a fever, we may have either under-
432 estimated or over-estimate cases of clinical malaria.

433 Fourth, the respondent was asked about their beliefs about whether an illness was malaria
434 in retrospect rather than prior to beginning treatment. It is possible that the treatment that was

435 chosen for the illness, and the outcome of the illness, influenced their perceptions of whether the
436 illness was malaria.

437 Finally, the generalizability of these results is limited by the fact that the survey occurred
438 over a few months (March-May) in one part of Eastern Uganda. As households were surveyed
439 over 9 weeks (the rainy season) it is unlikely that differences in measured prevalence rates are
440 due to variations in season. However, the patterns of beliefs and behavior that we found in this
441 study may vary by season or by location, and by the availability of ACTs relative to other anti-
442 malarial drugs. Moreover, since this entire region is highly endemic for malaria, our results may
443 not be relevant to low transmission and pre-elimination settings.

444 The likelihood that an individual with malaria is treated with an ACT depends on
445 whether they (or their caregivers) decide to seek care, the availability and cost of ACTs locally,
446 and their beliefs about the efficacy of those drugs [4,26,28,48]. Our results suggest that
447 additional policies are needed to encourage caregivers to seek immediate diagnostic testing and
448 treatment for febrile illnesses to ensure that those at highest risk of malaria receive appropriate
449 care.

450

451 **Acknowledgements**

452 The authors would like to thank Margaret McConnell and Michael Reich for thoughtful
453 comments and suggestions on previous versions of this manuscript.

454

455 **References**

456 1. World Health Organization. World Malaria Report 2015 [Internet]. 2015. Available:
457 <http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/>

- 458 2. World Health Organization. Guidelines for the treatment of malaria. 2015.
- 459 3. Private Sector Co-payment Mechanism. In: The Global Fund to fight AIDS, Tuberculosis
460 and Malaria [Internet]. [cited 22 Jan 2016]. Available:
461 <http://www.theglobalfund.org/en/privatesectorcopayment/>
- 462 4. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, et al. Monitoring fever
463 treatment behaviour and equitable access to effective medicines in the context of initiatives
464 to improve ACT access: baseline results and implications for programming in six African
465 countries. *Malaria Journal*. 2011;10: 327. doi:10.1186/1475-2875-10-327
- 466 5. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Marro J, et al.
467 Beyond Malaria — Causes of Fever in Outpatient Tanzanian Children. *New England*
468 *Journal of Medicine*. 2014;370: 809–817. doi:10.1056/NEJMoa1214482
- 469 6. Källander K, Nsungwa-Sabiiti J, Peterson S. Symptom overlap for malaria and
470 pneumonia—policy implications for home management strategies. *Acta Tropica*. 2004;90:
471 211–214. doi:10.1016/j.actatropica.2003.11.013
- 472 7. Bastiaens GJH, Bousema T, Leslie T. Scale-up of Malaria Rapid Diagnostic Tests and
473 Artemisinin-Based Combination Therapy: Challenges and Perspectives in Sub-Saharan
474 Africa. *PLoS Medicine*. 2014;11: e1001590. doi:10.1371/journal.pmed.1001590
- 475 8. Odaga J, Sinclair D, Lokong JA, Donegan S, Hopkins H, Garner P. Rapid diagnostic tests
476 versus clinical diagnosis for managing people with fever in malaria endemic settings. In:
477 The Cochrane Collaboration, editor. *Cochrane Database of Systematic Reviews*.
478 Chichester, UK: John Wiley & Sons, Ltd; 2014. Available:
479 <http://doi.wiley.com/10.1002/14651858.CD008998.pub2>
- 480 9. Cohen J, Fink G, Maloney K, Berg K, Jordan M, Svoronos T, et al. Introducing rapid
481 diagnostic tests for malaria to drug shops in Uganda: a cluster-randomized controlled trial.
482 *Bulletin of the World Health Organization*. 2015;93: 142–151. doi:10.2471/BLT.14.142489
- 483 10. Mabunda S, Aponte JJ, Tiago A, Alonso P. A country-wide malaria survey in Mozambique.
484 II. Malaria attributable proportion of fever and establishment of malaria case definition in
485 children across different epidemiological settings. *Malaria Journal*. 2009;8: 74.
486 doi:10.1186/1475-2875-8-74
- 487 11. Okiro EA, Snow RW. The relationship between reported fever and *Plasmodium falciparum*
488 infection in African children. *Malaria Journal*. 2010;9: 99. doi:10.1186/1475-2875-9-99
- 489 12. D'Acremont V, Lengeler C, Genton B. Reduction in the proportion of fevers associated
490 with *Plasmodium falciparum* parasitaemia in Africa: a systematic review. *Malaria Journal*.
491 2010;9: 240. doi:10.1186/1475-2875-9-240
- 492 13. Gething PW, Kirui VC, Alegana VA, Okiro EA, Noor AM, Snow RW. Estimating the
493 Number of Paediatric Fevers Associated with Malaria Infection Presenting to Africa's

- 494 Public Health Sector in 2007. Whitty CJM, editor. PLoS Medicine. 2010;7: e1000301.
495 doi:10.1371/journal.pmed.1000301
- 496 14. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of Plasmodium
497 falciparum malaria disease in sub-Saharan Africa. Nature Communications. 2014;5.
498 doi:10.1038/ncomms4136
- 499 15. Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health
500 impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison
501 of predictions from four mathematical models. The Lancet. 2016;387: 367–375.
502 doi:10.1016/S0140-6736(15)00725-4
- 503 16. Uganda Bureau of Statistics, ICF Macro. Uganda Malaria Indicator Survey 2009.
504 Calverton, Maryland, USA: UBOS and ICF Macro; 2010.
- 505 17. Cohen J, Fink G, Berg K, Aber F, Jordan M, Maloney K, et al. Feasibility of distributing
506 rapid diagnostic tests for malaria in the retail sector: evidence from an implementation
507 study in Uganda. PLoS ONE. 2012;7: e48296. doi:10.1371/journal.pone.0048296
- 508 18. World Health Organization, Special Programme for Research and Training in Tropical
509 Diseases, Foundation for Innovative New Diagnostics, Centers for Disease Control (U.S.).
510 Malaria rapid diagnostic test performance results of WHO product testing of malaria RDTs:
511 4 (2012). [Internet]. Geneva, Switzerland: World Health Organization on behalf of the
512 Special Programme for Research and Training in Tropical Diseases; 2012. Available:
513 http://apps.who.int/iris/bitstream/10665/77748/1/9789241504720_eng.pdf
- 514 19. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A Review of
515 Malaria Diagnostic Tools: Microscopy and Rapid Diagnostic Test (RDT). The American
516 Journal of Tropical Medicine and Hygiene. 2007;77: 119–127.
- 517 20. Aydin-Schmidt B, Mubi M, Morris U, Petzold M, Ngasala BE, Premji Z, et al. Usefulness
518 of Plasmodium falciparum-specific rapid diagnostic tests for assessment of parasite
519 clearance and detection of recurrent infections after artemisinin-based combination therapy.
520 Malaria Journal. 2013;12: 349. doi:10.1186/1475-2875-12-349
- 521 21. Swarthout TD, Counihan H, Senga R, van den Broek I. Paracheck-Pf® accuracy and
522 recently treated Plasmodium falciparum infections: is there a risk of over-diagnosis?
523 Malaria Journal. 2007;6: 58. doi:10.1186/1475-2875-6-58
- 524 22. Kyabayinze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H. Operational
525 accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for
526 Plasmodium falciparum malaria in a hyperendemic region of Uganda. Malaria Journal.
527 2008;7: 221. doi:10.1186/1475-2875-7-221
- 528 23. World Health Organization. World Malaria Report 2014 [Internet]. 2014. Available:
529 http://www.who.int/malaria/publications/world_malaria_report_2014/en/

- 530 24. Smith DL, Guerra CA, Snow RW, Hay SI. Standardizing estimates of the Plasmodium
531 falciparum parasite rate. *Malaria Journal*. 2007;6: 131. doi:10.1186/1475-2875-6-131
- 532 25. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual
533 acquisition of immunity to severe malaria with increasing exposure. *Proceedings of the*
534 *Royal Society B: Biological Sciences*. 2015;282: 20142657–20142657.
535 doi:10.1098/rspb.2014.2657
- 536 26. Shah JA, Emina JBO, Eckert E, Ye Y. Prompt access to effective malaria treatment among
537 children under five in sub-Saharan Africa: a multi-country analysis of national household
538 survey data. *Malaria Journal*. 2015;14. doi:10.1186/s12936-015-0844-7
- 539 27. Vialle-Valentin CE, LeCates RF, Zhang F, Ross-Degnan D. Treatment of Febrile illness
540 with artemisinin combination therapy: prevalence and predictors in five African household
541 surveys. *Journal of Pharmaceutical Policy and Practice*. 2015;8. doi:10.1186/s40545-014-
542 0024-0
- 543 28. Cohen JM, Sabot O, Sabot K, Gordon M, Gross I, Bishop D, et al. A pharmacy too far?
544 Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based
545 combination therapies through private drug shops. *BMC Health Services Research*.
546 2010;10: S6. doi:10.1186/1472-6963-10-S1-S6
- 547 29. Rutebemberwa E, Kallander K, Tomson G, Peterson S, Pariyo G. Determinants of delay in
548 care-seeking for febrile children in eastern Uganda. *Tropical Medicine & International*
549 *Health*. 2009;14: 472–479. doi:10.1111/j.1365-3156.2009.02237.x
- 550 30. Getahun A, Deribe K, Deribew A. Determinants of delay in malaria treatment-seeking
551 behaviour for under-five children in south-west Ethiopia: a case control study. *Malaria*
552 *Journal*. 2010;9: 320. doi:10.1186/1475-2875-9-320
- 553 31. Chuma J, Okungu V, Molyneux C. Barriers to prompt and effective malaria treatment
554 among the poorest population in Kenya. *Malaria Journal*. 2010;9: 144. doi:10.1186/1475-
555 2875-9-144
- 556 32. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data--or tears: an
557 application to educational enrollments in states of India. *Demography*. 2001;38: 115–132.
- 558 33. StataCorp. *Stata Statistical Software: Release 11*. College Station, TX: STataCorp LP;
559 2009.
- 560 34. Kazembe LN, Appleton CC, Kleinschmidt I. Choice of treatment for fever at household
561 level in Malawi: examining spatial patterns. *Malaria Journal*. 2007;6: 40. doi:10.1186/1475-
562 2875-6-40
- 563 35. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission
564 from malaria patients by artemisinin combination therapies: a pooled analysis of six
565 randomized trials. *Malaria Journal*. 2008;7: 125. doi:10.1186/1475-2875-7-125

- 566 36. Peak CM, Thuan PD, Britton A, Nguyen TD, Wolbers M, Thanh NV, et al. Measuring the
567 Association Between Artemisinin-Based Case Management and Malaria Incidence in
568 Southern Vietnam, 1991-2010. *American Journal of Tropical Medicine and Hygiene*.
569 2015;92: 811–817. doi:10.4269/ajtmh.14-0461
- 570 37. Korenromp E, Mahiané G, Hamilton M, Pretorius C, Cibulskis R, Lauer J, et al. Malaria
571 intervention scale-up in Africa: effectiveness predictions for health programme planning
572 tools, based on dynamic transmission modelling. *Malaria Journal*. 2016;15.
573 doi:10.1186/s12936-016-1461-9
- 574 38. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, et al. Reduction of
575 Malaria Transmission to Anopheles Mosquitoes with a Six-Dose Regimen of Co-
576 Artemether. Garner P, editor. *PLoS Medicine*. 2005;2: e92.
577 doi:10.1371/journal.pmed.0020092
- 578 39. Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong J, et al. Rapid
579 testing for malaria in settings where microscopy is available and peripheral clinics where
580 only presumptive treatment is available: a randomised controlled trial in Ghana. *BMJ*.
581 2010;340: c930–c930. doi:10.1136/bmj.c930
- 582 40. Kabaghe AN, Visser BJ, Spijker R, Phiri KS, Grobusch MP, van Vugt M. Health workers’
583 compliance to rapid diagnostic tests (RDTs) to guide malaria treatment: a systematic review
584 and meta-analysis. *Malaria Journal*. 2016;15. doi:10.1186/s12936-016-1218-5
- 585 41. Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Age-
586 Patterns of Malaria Vary with Severity, Transmission Intensity and Seasonality in Sub-
587 Saharan Africa: A Systematic Review and Pooled Analysis. Noor AM, editor. *PLoS ONE*.
588 2010;5: e8988. doi:10.1371/journal.pone.0008988
- 589 42. Cohen JL, Yadav P, Moucheraud C, Alphas S, Larson PS, Arkedis J, et al. Do Price
590 Subsidies on Artemisinin Combination Therapy for Malaria Increase Household Use?:
591 Evidence from a Repeated Cross-Sectional Study in Remote Regions of Tanzania. Yukich
592 J, editor. *PLoS ONE*. 2013;8: e70713. doi:10.1371/journal.pone.0070713
- 593 43. Doolan DL, Dobano C, Baird JK. Acquired Immunity to Malaria. *Clinical Microbiology*
594 *Reviews*. 2009;22: 13–36. doi:10.1128/CMR.00025-08
- 595 44. Schellenberg JR, Smith T, Alonso PL, Hayes RJ. What is clinical malaria? Finding case
596 definitions for field research in highly endemic areas. *Parasitol Today (Regul Ed)*. 1994;10:
597 439–442.
- 598 45. Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions for
599 malaria in endemic. *Statistics in Medicine*. 1994;13: 2345–2358.
600 doi:10.1002/sim.4780132206
- 601 46. Ghai RR, Thurber MI, El Bakry A, Chapman CA, Goldberg TL. Multi-method assessment
602 of patients with febrile illness reveals over-diagnosis of malaria in rural Uganda. *Malaria*
603 *Journal*. 2016;15. doi:10.1186/s12936-016-1502-4

604 47. Uganda Bureau of Statistics (UBOS), ICF International. Uganda Malaria Indicator Survey
 605 2014-15. Kampala, Uganda and Rockville, Maryland: UBOS and ICF International; 2015.

606 48. Hensen B, Paintain L, Shretta R, Bruce J, Jones C, Webster J. Taking stock: provider
 607 prescribing practices in the presence and absence of ACT stock. *Malaria Journal*. 2011;10:
 608 218. doi:10.1186/1475-2875-10-218


609
 610
 611

612 Supporting Information

613 **S1 Dataset. Household and Illness Survey.** Household data from baseline survey and illness
 614 data from final survey round including malaria rapid diagnostic test result. Sample is limited to
 615 those who had a fever in the two weeks prior to the survey.

616
 617


Malaria Beliefs by Age and Prevalence Conditional on Fever



618

619 **S1 Fig. Robustness of Malaria Beliefs by Age and Prevalence.** The figures in the left column
 620 show the proportion of respondents who reported that the illness was malaria. The figures on the
 621 right show the mean of the respondents' perceived likelihood that the illness was malaria on a
 622 scale of 0-10 (divided by 10 so as to use a similar scale). Points show mean of the outcome
 623 within 5-year age groups or 0.1 units of village prevalence. A local linear regression line is also
 624 plotted and the grey shaded areas indicate 95% confidence intervals. Sample is limited to
 625 patients who were not previously tested for malaria.


626



627

628 **S2 Fig. Distribution of Village Malaria Prevalence Rates.** Positivity Rates are based on the
 629 RDT performed at the end of the survey on children whose parents/caregivers gave consent to
 630 their being tested. Sample is limited to children between the ages of 2 and 10.


Clinical Malaria Episodes Treated with ACTs



631

632 **S3 Fig. ACT Use for Clinical Malaria Episodes by Age and by Village Prevalence.** (A) The
 633 proportion of clinical malaria episodes (febrile patients who tested positive on the RDT) treated
 634 with ACTs by the age of the patient. (B) The proportion of clinical malaria episodes treated with
 635 ACTs by the village prevalence rate. Figure shows mean of the outcome within 1-year age
 636 groups (for ages under 5) or 5-year age groups (for ages 5 and above) and 0.10 units of village
 637 prevalence. A local linear regression line is also plotted and the grey shaded areas indicate 95%
 638 confidence intervals. Data is limited to patients who had a fever in the two weeks prior to the
 639 survey and to patients under age 5 (in B). Ages above 60 are excluded because of small sample
 640 size (in A).

ACT Availability by Village Prevalence



641

642 **S4 Fig. ACT Availability in Health Facilities and Drugs Shops by Village Prevalence.** The
 643 proportion of health facilities (blue) and drug shops (red) by village prevalence that had ACTs
 644 available at the time of the survey. Health facilities include public clinics, health centers or
 645 hospitals. Points indicate mean proportion for each village and a separate local polynomial
 646 regression line is also included for health facilities and drug shops.

647

<i>Coefficient on:</i>	Odds Febrile Episode Tested Positive for Malaria		Odds Febrile Episode Treated with ACT		Odds RDT-Positive Febrile Episode Treated with ACT	
	OR	aOR	OR	aOR	OR	aOR
Patient Under 5	2.66** [1.99,3.56]	2.65** [1.95,3.61]	1.24 [0.92,1.68]	1.2 [0.87,1.64]	1.47 [0.98,2.21]	1.47 [0.96,2.25]
Patient Aged 5-14	3.21** [2.36,4.37]	3.34** [2.40,4.66]	1.19 [0.88,1.62]	1.29 [0.94,1.77]	1.11 [0.74,1.64]	1.4 [0.91,2.14]
Patient Aged 15 or Above	Ref. Group	Ref. Group	Ref. Group	Ref. Group	Ref. Group	Ref. Group
P-value: Coefficient on Under 5 for ACT Treatment= Coefficient on Under 5 for Positivity	Ref Group	Ref Group	0.00	0.00	0.02	0.04
P-value: Coefficient on Ages 5-14 for ACT Treatment = Coefficient on Ages 5-14 for Positivity	Ref Group	Ref Group	0.00	0.00	0.00	0.00
Proportion Tested Positive/Treated with ACT	0.52	0.52	0.42	0.42	0.4	0.39
Number of Observations	1335	1256	1335	1256	695	650

648

649

650

651

652

653

654

655

656

657

S1 Table. Effect of age on Malaria Positivity and ACT Use. Table shows un-adjusted and adjusted logistic regression results of the association between age and the odds that a febrile individual tested positive for malaria, the odds that a febrile individual was treated with an ACT, and the odds that an RDT-positive febrile episode was treated with an ACT. The control variables for the adjusted regressions are as follows: respondent's education level, whether the respondent can read English, household wealth quintile, distance to closest clinic, health center, hospital and drug shop, and whether the closest licensed drug shop stocked ACTs. Equality of coefficients were tested using the "suest" command in STATA. 95% confidence intervals are in brackets and adjusted for clustering at the village level. *p<0.05, **p<0.01.

<i>Coefficient on:</i>	Odds Febrile Episode Tested Positive for Malaria		Odds Febrile Episode Treated with ACT		Odds RDT-Positive Febrile Episode Treated with ACT	
	OR	aOR	OR	aOR	OR	aOR
Standardized Village Prevalence Rate	2.03** [1.63,2.54]	1.68** [1.31,2.16]	0.83 [0.66,1.05]	0.75* [0.60,0.93]	0.7 [0.46,1.07]	0.58** [0.38,0.87]
P-value: Coefficient on Village Prevalence for ACT Treatment = Coefficient on Village Prevalence for Positivity	Ref Group	Ref Group	0.000	0.000	0.000	0.000
Proportion Tested Positive/Treated with ACT	0.59	0.58	0.44	0.43	0.44	0.43
Number of Observations	581	534	581	534	340	311

658

659 **S2 Table. Effect of Village Prevalence on Malaria Positivity and ACT Use among Children**

660 **Under Age 5.** Table shows un-adjusted and adjusted logistic regression results of the
661 association between the standardized village prevalence rate and the odds that a child under 5
662 tested positive for malaria, the odds that a child under 5 was treated with an ACT, and the odds
663 that a clinical malaria episode (fever and RDT positive) in a child under 5 was treated with an
664 ACT. Individual is excluded from calculation of village prevalence rate. The control variables
665 for the adjusted regressions are as follows: respondent’s education level, whether the respondent
666 can read English, household wealth quintile, distance to closest clinic, health center, hospital and
667 drug shop, and whether the closest licensed drug shop stocked ACTs. Equality of coefficients
668 were tested using the “suest” command in STATA. 95% confidence intervals are in brackets and
669 adjusted for clustering at the village level. *p<0.05, **p<0.01.

<i>Coefficient on:</i>	Odds Respondent Believed Illness Was Malaria			
	OR	aOR	OR	aOR
Patient Under 5	0.94 [0.72,1.24]	0.97 [0.71,1.33]		
Patient Aged 5-14	1.04 [0.71,1.53]	1.17 [0.80,1.70]		
Standardized Village Prevalence Rate			0.87 [0.70,1.08]	0.89 [0.70,1.14]
Proportion Believed Illness Was Malaria	0.3	0.3	0.29	0.29
Number of Observations	1170	1103	508	469

670

671 **S3 Table. Malaria Beliefs by Patient Age and by Village Prevalence.** Un-adjusted and
672 adjusted logistic regression results of the association between patient age, or the village
673 prevalence rate, and the odds that a respondent believed the febrile illness was malaria. Adjusted
674 logistic regressions include the following control variables: respondent's education level,
675 whether the respondent can read English, household wealth quintile, distance to closest clinic,
676 health center, hospital and drug shop, and whether the closest licensed drug shop stocked ACTs.
677 Sample is limited to individuals who were not previously tested for malaria. Regressions with
678 village prevalence are limited to children under the age of 5. Individuals who were previously
679 tested for malaria are excluded. 95% confidence intervals are in brackets and are adjusted for
680 clustering at the village level. *p<0.05, **p<0.01.

681

682

	Stepwise Logistic Regression	
	Odds Febrile Episode Treated with ACT	Odds RDT-Positive Febrile Episode Treated with ACT
	(1)	(2)
Respondent Believed Illness Was Malaria	2.47** [1.82,3.34]	2.65** [1.80,3.92]
Patient is Aged 15 and above	Ref. Group	Ref. Group

Patient Aged 5-14		1.45 [0.90,2.34]
Patient Under Age 5		1.42 [0.89,2.28]
Standardized Village Prevalence Rate	0.86 [0.73,1.01]	0.74* [0.55,1.00]
Respondent Has No Education	Ref. Group	Ref. Group
Respondent Has Some Primary Education	2.24** [1.45,3.44]	1.90* [1.11,3.24]
Respondent Has Some Secondary Education	2.24** [1.24,4.05]	1.78 [0.88,3.60]
Respondent Can Read English		
Household In First Wealth Quintile (Poorest)	Ref. Group	Ref. Group
Household In Second Wealth Quintile		
Household In Third Wealth Quintile		
Household In Fourth Wealth Quintile	1.54* [1.01,2.33]	
Household In Fifth Wealth Quintile (Richest)	1.39 [0.88,2.20]	
Household distance to closest health center (km)		
Household distance to closest hospital (km)		0.98 [0.95,1.01]

Household distance to closest clinic (km)

Household distance to closest drug shop(km)	1.15* [1.02,1.28]	1.20** [1.06,1.37]
ACTs available at closest licensed drug shop	1.50** [1.11,2.04]	1.74* [1.10,2.76]
Proportion of people who took an ACT	0.4	0.39
Number of Observations	1103	597

683

684 **S4 Table. Factors Associated with ACT treatment using Stepwise Multivariate Logistic**
685 **Regression.** Results are from a stepwise backward-selection estimation of a logistic model
686 (using the “stepwise” command in STATA). The significance level for removal from the model
687 was 0.2. 95% confidence intervals are in brackets and are adjusted for clustering at the village
688 level. *p<0.05, **p<0.01

